Treating Hepatitis C in Jails: A Critical Step Towards Elimination
Addressing hepatitis C virus (HCV) infection within jail systems is a vital public health strategy, as incarceration represents a key opportunity to reach individuals often marginalized from traditional healthcare, according to recent research and public health officials. This story matters because HCV remains a significant global health burden, and innovative approaches are needed to meet elimination goals.
Hepatitis C and the Criminal Justice System
Individuals involved with the criminal justice system are disproportionately affected by HCV. The Centers for Disease Control and Prevention (CDC) reports that people who inject drugs are at highest risk for infection, and this population is overrepresented in jails and prisons. While prisons have increasingly implemented HCV screening and treatment programs, jails – which typically hold individuals for shorter periods and have higher turnover rates – have lagged behind. Estimates suggest that between 12% and 35% of individuals incarcerated in county jails in the United States have been exposed to HCV, according to research from the University of California, Berkeley [https://publichealth.berkeley.edu/articles/spotlight/research/hepatitis-c-ignored-in-many-jails].
Challenges and Opportunities in Jail-Based Treatment
A major hurdle to treating HCV in jails has been the assumption that short lengths of stay make treatment impractical. However, a study led by Shelley Facente at UC Berkeley School of Public Health challenged this notion. Published in the Journal of Correctional Health Care, the study found that a significant number of individuals incarcerated in San Francisco jails – 79 out of 320 between 2016 and 2021 – remained in custody for at least eight weeks after diagnosis, long enough to complete a full course of direct-acting antiviral (DAA) treatment. Furthermore, 56% of those incarcerated during this period had untreated HCV, a percentage significantly higher than in the general population.
Cost-Effectiveness of Jail-Based Interventions
Recent research strengthens the argument for jail-based HCV treatment by demonstrating its cost-effectiveness. A study published in JAMA Internal Medicine [https://jamanetwork-com.libproxy.ajou.ac.kr/journals/jamainternalmedicine/article-abstract/2846745] used a network simulation model to assess the impact of jail-based HCV interventions. The findings indicated that these interventions could reduce HCV incidence and HCV-related deaths by 47% and 40%, respectively, with a cost of $11,000 per quality-adjusted life-year gained – a figure considered highly cost-effective. The study also found that providing treatment in jails yielded greater economic value than testing alone.
Successful Models and National Efforts
The Veterans Health Administration (VHA) provides a successful model for treating HCV in formerly incarcerated individuals. A study published in the American Journal of Public Health [https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2022.307152] found that the VHA effectively treated individuals with prior incarceration, demonstrating the feasibility of providing comprehensive care to this population. Nationally, the U.S. Department of Health and Human Services launched a National Hepatitis C Elimination Program in 2023, with a key focus on supporting HCV treatment within correctional facilities.
Overcoming Barriers and Expanding Access
Despite the evidence supporting jail-based HCV treatment, barriers remain. These include logistical challenges related to high turnover rates, limited resources, and potential staff hesitancy. However, interviews conducted by Facente’s team revealed enthusiasm for treatment from both jail staff and incarcerated individuals, as well as a lack of awareness about community-based treatment options. Addressing these barriers requires increased funding, training for correctional staff, and improved linkages to care post-release. According to a commentary published in JAMA Internal Medicine [https://jamanetwork-com.libproxy.ajou.ac.kr/journals/jamainternalmedicine/article-abstract/2846748], scaling up these programs will be essential to achieving national elimination goals. The World Health Organization aims to eliminate HCV globally by 2030 [https://www.who.int/news-room/fact-sheets/detail/hepatitis-c].
Looking Ahead
Treating HCV in jails is not only a medical imperative but also a matter of social justice. By providing access to effective treatment within correctional facilities, public health officials can reduce suffering, prevent further transmission, and contribute to the ultimate elimination of this curable disease. Read more on Globally Pulse Health.
